A61P1/02

Wound healing composition

The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.

Wound healing composition

The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.

COMPOSITIONS COMPRISING ELECTROHYDRODYNAMICALLY OBTAINED FIBRES FOR ADMINISTRATION OF SPECIFIC DOSAGES OF AN ACTIVE SUBSTANCE TO SKIN OR MUCOSA
20230210784 · 2023-07-06 ·

The present invention relates to electrospun fibers comprising i) a hydrophilic polymer that is soluble in a first solvent, ii) a bioadhesive substance that is slightly soluble in said first solvent, iii) optionally, a drug substance.

Dental composition containing platinum nanoparticles
11547639 · 2023-01-10 · ·

The present invention provides a dental composition that exhibits excellent long-lasting antibacterial activity even as a cured product, and that excels in aesthetic quality with no discoloration occurring in water or in hydrogen sulfide. The present invention relates to a dental composition comprising a platinum nanoparticle (a) uncoated with a colloidal protective material.

Methods and compositions for reversing or mitigating skin aging

A method for reversing or mitigating skin aging comprising topically applying a composition which comprises at least one oxidant, and at least one fluorescent dye capable of activating the oxidant and illuminating said composition for a time sufficient to activate the at least one oxidant.

Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. ##STR00001##
wherein A, Y, Z, X.sub.1, X.sub.2, X.sub.3, R.sub.1, R.sub.3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

HU specific interfering agents

Methods of and compositions for breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of an interfering agent capable of specifically competing, titrating, or inhibiting the binding of an HU protein to a microbial DNA. By competing with HU proteins that bind to DNA scaffold in the biofilm, these interfering agents destabilize the biofilm leading to destruction and removal of the biofilm by the immune system. Further method and composition aspects are contemplated in relation to infections caused by bacteria that export an HU protein.

Self-assembled amino acid supramolecular polymer, preparation method therefor, and application thereof
11540993 · 2023-01-03 · ·

Disclosed are a novel self-assembled amino acid supramolecular polymer, a preparation method therefor, and an application thereof. The self-assembled supramolecular polymer is N-lauroyl-L-alanyl-L-alanine or a salt thereof, and the salt thereof comprises sodium N-lauroyl-L-alanyl-L-alaninate and potassium N-lauroyl-L-alanyl-L-alaninate. The disclosed polymer is more effective at inhibiting bacteria and removing pesticides, and can be widely applied to the daily chemical, agricultural, and pharmaceutical industries. Further disclosed are three methods for preparing the compound. The methods produce products in high yields and are suitable for industrial production.

LACTOBACILLUS SALIVARIUS LS97 AND APPLICATION THEREOF
20220409681 · 2022-12-29 ·

Disclosed is a Lactobacillus salivarius LS97 and an application thereof. The strain was deposited in the China General Microbiological Culture Collection Center on Dec. 10, 2018 with a deposit number of CGMCC NO.16922 and a classification name of Lactobacillus salivarius, the deposit address being China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No. 1 West Beichen Road, Chaoyang District, Beijing 100101, China. The Lactobacillus salivarius LS97 can effectively inhibit the growth of Streptococcus sobrinus.

LACTOBACILLUS SALIVARIUS LS97 AND APPLICATION THEREOF
20220409681 · 2022-12-29 ·

Disclosed is a Lactobacillus salivarius LS97 and an application thereof. The strain was deposited in the China General Microbiological Culture Collection Center on Dec. 10, 2018 with a deposit number of CGMCC NO.16922 and a classification name of Lactobacillus salivarius, the deposit address being China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No. 1 West Beichen Road, Chaoyang District, Beijing 100101, China. The Lactobacillus salivarius LS97 can effectively inhibit the growth of Streptococcus sobrinus.